Overview
The marketing authorisation for Sprimeo has been withdrawn at the request of the marketing-authorisation holder.
Sprimeo : EPAR - Summary for the public
English (EN) (274.9 KB - PDF)
български (BG) (342.15 KB - PDF)
español (ES) (259.26 KB - PDF)
čeština (CS) (311.96 KB - PDF)
dansk (DA) (258.54 KB - PDF)
Deutsch (DE) (260.03 KB - PDF)
eesti keel (ET) (258.16 KB - PDF)
ελληνικά (EL) (347.65 KB - PDF)
français (FR) (319.2 KB - PDF)
italiano (IT) (259.5 KB - PDF)
latviešu valoda (LV) (316.27 KB - PDF)
lietuvių kalba (LT) (282.88 KB - PDF)
magyar (HU) (307.75 KB - PDF)
Malti (MT) (311.55 KB - PDF)
Nederlands (NL) (259.07 KB - PDF)
polski (PL) (372.79 KB - PDF)
português (PT) (335.06 KB - PDF)
română (RO) (282.51 KB - PDF)
slovenčina (SK) (310.95 KB - PDF)
slovenščina (SL) (308.01 KB - PDF)
Suomi (FI) (318.25 KB - PDF)
svenska (SV) (319.06 KB - PDF)
Product information
Sprimeo : EPAR - Product Information
English (EN) (1.01 MB - PDF)
български (BG) (2.32 MB - PDF)
español (ES) (1.03 MB - PDF)
čeština (CS) (1.65 MB - PDF)
dansk (DA) (1.09 MB - PDF)
Deutsch (DE) (1.14 MB - PDF)
eesti keel (ET) (1.09 MB - PDF)
ελληνικά (EL) (2.29 MB - PDF)
français (FR) (1.15 MB - PDF)
íslenska (IS) (1.1 MB - PDF)
italiano (IT) (1.14 MB - PDF)
latviešu valoda (LV) (1.74 MB - PDF)
lietuvių kalba (LT) (1.06 MB - PDF)
magyar (HU) (1.7 MB - PDF)
Malti (MT) (1.81 MB - PDF)
Nederlands (NL) (1.08 MB - PDF)
norsk (NO) (1.11 MB - PDF)
polski (PL) (1.73 MB - PDF)
português (PT) (1.02 MB - PDF)
română (RO) (1.07 MB - PDF)
slovenčina (SK) (1.79 MB - PDF)
slovenščina (SL) (1.68 MB - PDF)
Suomi (FI) (1.03 MB - PDF)
svenska (SV) (1019.89 KB - PDF)
Latest procedure affecting product information: II/0039
04/07/2012
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Sprimeo : EPAR - All Authorised presentations
English (EN) (345 KB - PDF)
български (BG) (427.3 KB - PDF)
español (ES) (369.76 KB - PDF)
čeština (CS) (387.75 KB - PDF)
dansk (DA) (344.96 KB - PDF)
Deutsch (DE) (351.03 KB - PDF)
eesti keel (ET) (348.09 KB - PDF)
ελληνικά (EL) (430.1 KB - PDF)
français (FR) (373.1 KB - PDF)
íslenska (IS) (367.27 KB - PDF)
italiano (IT) (367.54 KB - PDF)
latviešu valoda (LV) (369.95 KB - PDF)
lietuvių kalba (LT) (374.13 KB - PDF)
magyar (HU) (385.82 KB - PDF)
Malti (MT) (389.44 KB - PDF)
Nederlands (NL) (365.63 KB - PDF)
norsk (NO) (369.99 KB - PDF)
polski (PL) (399.45 KB - PDF)
português (PT) (369.22 KB - PDF)
română (RO) (369.48 KB - PDF)
slovenčina (SK) (390.13 KB - PDF)
slovenščina (SL) (399.01 KB - PDF)
Suomi (FI) (344.56 KB - PDF)
svenska (SV) (370.53 KB - PDF)
Product details
- Name of medicine
- Sprimeo
- Active substance
- aliskiren
- International non-proprietary name (INN) or common name
- aliskiren
- Therapeutic area (MeSH)
- Hypertension
- Anatomical therapeutic chemical (ATC) code
- C09XA02
Pharmacotherapeutic group
Agents acting on the renin-angiotensin systemTherapeutic indication
Treatment of essential hypertension.
Authorisation details
- EMA product number
- EMEA/H/C/000851
- Marketing authorisation holder
- Novartis Europharm Ltd.
Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom - Marketing authorisation issued
- 22/08/2007
- Revision
- 5
Assessment history
Sprimeo : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (528.14 KB - PDF)
Sprimeo-H-C-xxxx-WS-0069 : EPAR - Assessment Report - Variation
English (EN) (293.47 KB - PDF)
Sprimeo-H-C-851-A-20-0067 : EPAR - Assessment Report - Variation
English (EN) (655.03 KB - PDF)
Sprimeo-H-C-xxxx-WS-0169 : EPAR - Assessment Report - Variation
English (EN) (384.18 KB - PDF)
Sprimeo-H-C-xxxx-WS-0037 : EPAR - Assessment Report - Variation
English (EN) (3.03 MB - PDF)
News on Sprimeo
More information on Sprimeo
Questions and answers on the review aliskiren-containing medicines
English (EN) (60.98 KB - PDF)
Questions and answers on ongoing review of aliskiren-containing medicines
English (EN) (65.3 KB - PDF)
Public statement on Sprimeo: Withdrawal of the marketing authorisation in the European Union
English (EN) (43.05 KB - PDF)